The effect of galsulfase enzyme replacement therapy on the growth of patients with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome)
Keywords: ASB; Arylsulfatase B; CDC; Centers for Disease Control and Prevention; ERT; Enzyme replacement therapy; GAG; Glycosaminoglycans; MPS VI; Mucopolysaccharidosis VI; uGAG; Urinary glycosaminoglycans; Mucopolysaccharidosis; Mucopolysaccharidosis VI; Maroteaux